SomaLogic Partners with Rensk Bio to Expand into the Chinese Market

Shanghai and Boulder, Colorado (May 10, 2023) — SomaLogic, a leader in proteomics technology, today announced a collaboration with Renke Biotechnology to provide its 7000-plex SomaScan^®Proteomics testing technology services, while also providing SomaScan data to its customers. Renke Bio has become SomaLogic’s first authorized partner in China.

“We are delighted to partner with SomaLogic and become its first authorized partner in Shanghai. We hope to help expand its presence in Asia by providing next-generation proteomics products,” said Mr. Qiu Yannan, Founder and CEO of Renke Biology and Yunzhun Medicine. “We believe that this collaboration with SomaLogic will enable Chinese customers to leverage the SomaScan assay as a powerful tool to investigate the underlying mechanisms of physiological and pathological processes in disease areas such as cardiovascular disease, liver disease, cancer, and diabetes.”

Founded in 2006, Renke Biology is a leading technology provider in the fields of life sciences and translational medicine in China, serving over 1,000 clients across academic research, biopharmaceuticals, clinical translation, and in vitro diagnostics. Today, Renke Biology will become the first company in China to offer SomaLogic’s proteomics testing technology.

“For SomaLogic, the Chinese proteomics market holds immense growth potential and is an exciting marketplace,” said Mr. Adam Taich, CEO of SomaLogic. “Researchers in China have long recognized the value of this market-leading technology. As our trusted partner and first licensed collaborator, we are confident that Renke Bio will unlock the full potential of our solutions in China through SomaLogic’s SomaScan platform.”

Renke Biology, together with Singapore’s Molecular Genomics and Japan’s FonesLife, has become one of SomaLogic’s first authorized partners in the Asia-Pacific region. Earlier this year, Group 42 Healthcare became the first authorized partner for SomaLogic in the Middle East.

SomaLogic is a global leader in the field of proteomics technology, dedicated to advancing drug development and the discovery and validation of biomarkers. Requiring only 55 microliters of plasma or serum, SomaLogic can currently measure 7,000 proteins, covering more than one-third of the approximately 20,000 proteins in the human body—twice the coverage of other proteomics platforms. For over two decades, we have supported pharmaceutical companies, academic institutions, and contract research organizations (CROs), which rely on our protein detection and analysis technologies to drive progress in drug development, disease diagnosis, and treatment across oncology, diabetes, cardiovascular, hepatic, and metabolic diseases. For more information, please visitwww.somalogic.com, and follow our LinkedIn account @somalogic.